PKU Hi-Tech Huatai Pharmaceuticals Blacklisted from China’s Volume-Based Procurement Following Quality Compliance Failures
PKU Hi-Tech Huatai Pharmaceuticals Co., Ltd. has been blacklisted from China’s national volume-based procurement (VBP)...
VBP (voluem-based procurement)
China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
The National Drug Alliance Procurement Office, administrator of China’s volume-based procurement (VBP) program, announced the...
China Imposes Historic Four-Year VBP Ban on Fu Kang Ren, Hetero Labs for Supply Failures; Hehe and Tiantaishan Also Penalized
The National Drug Alliance Procurement Office has revoked the Volume-Based Procurement (VBP) winning bid qualifications...
NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons
China’s National Healthcare Security Administration (NHSA) conducted the 6th volume-based procurement (VBP) tender for high-value...
SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round
China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the...
VBP 11th Finalizes 389 Participants, 3.7 Billion Doses Set for Centralized Procurement
The Office of the National Drug Joint Procurement (ONDJP) published the conclusive enterprise roster for...
National Joint Procurement Office Announces 11th Round VBP, AstraZeneca Dapagliflozin Leads Demand
On October 11, 2025, the National Joint Procurement Office (NJPO) released the full company list for...
National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai
The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...
China Drug Procurement: Centralized Rules Shape 11th Round Of VBP
The Joint Procurement Office of the National Healthcare Security Administration (NHSA) published the definitive rules...
NHSA Updates Volume-Based Procurement Policy for Medical Institutions in 11th VBP Tender
The National Healthcare Security Administration (NHSA) has released Q&As on the medical institutions’ volumes filing...
NHSA Announces Reforms to Centralized Drug Procurement Policies Beyond Lowest Price
The National Healthcare Security Administration (NHSA) held a press conference today on the “High-Quality Completion...
NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism
The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...
CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8%...
Shanghai Healthcare Administration Pushes for 11th Round of VBP
Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...
Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation
China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...
Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics
The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized...
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement
Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...
HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process
HMZS Biopharmaceutical, a Chinese company that won a bid for its phloroglucinol in the 10th...
National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...